Wellcome Open Research, 2022 Background: Blockade of tumour necrosis factor (anti-TNF) is effective in patients with Crohn’s Disease but has been associated with infection risk and neurological complications such as demyelination.
David Smith +16 more
doaj +1 more source
Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNF alpha therapy [PDF]
, 2004 Regulatory T cells have been clearly implicated in the control of disease in murine models of autoimmunity. The paucity of data regarding the role of these lymphocytes in human autoimmune disease has prompted us to examine their function in patients with
Jamie G. Evans +13 more
core +1 more source
Comparison of loss of response between anti-tumor necrosis factor alone and combined use with immunomodulators in patients with inflammatory bowel disease [PDF]
The Korean Journal of Internal Medicine, 2021 Background/Aims Combination therapy with immunomodulators (IMMs) was proposed as a strategy to prevent the development of loss of response (LOR) to anti-tumor necrosis factor (TNF) for patients with inflammatory bowel disease (IBD).
Seung Wook Hong +8 more
doaj +1 more source
Egyptian Journal of Chest Disease and Tuberculosis, 2015 Introduction: Patients with rheumatoid arthritis (RA) have increased susceptibility to infection. The risk of acquiring infection including tuberculosis (TB) in RA may be increased in patients receiving any immuno-suppressive medication including anti ...
Saad Rabie Samra +3 more
doaj +1 more source
Safety of anti-TNF agents in patients with compensated cirrhosis: a case-control study
Therapeutic Advances in Gastroenterology, 2021 Background: There is limited data on the use of anti-TNF agents in patients with concomitant cirrhosis. The aim of this study is to assess the safety of anti-TNF agents in patients with compensated cirrhosis who used these medications for the treatment ...
Nikhil Kapila +9 more
doaj +1 more source
Frontiers in Pharmacology, 2022 Purpose: Anti-tumour necrosis factor-alpha (TNF-α) agents are often used for Behçet’s disease (BD) in clinical practice, but they have not been validated by a high level of evidence.
Xinwei Zhou +4 more
doaj +1 more source
Asian Organization for Crohn's and Colitis and Asia Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Part 2: management [PDF]
Intestinal Research, 2018 Because anti-tumor necrosis factor (anti-TNF) therapy has become increasingly popular in many Asian countries, the risk of developing active tuberculosis (TB) among anti-TNF users may raise serious health problems in this region.
Dong Il Park +22 more
doaj +1 more source
Journal of Functional Biomaterials, 2022 Neutralising monoclonal antibodies for tumour necrosis factor (TNF) has been widely used to treat Crohn’s disease (CD) in clinical practice. However, differential individual response necessitates a therapeutic response assessment of anti-TNF agents in CD
Min Seob Kwak +4 more
doaj +1 more source
The effect of three years of TNF alpha blocking therapy on markers of bone turnover and their predictive value for treatment discontinuation in patients with ankylosing spondylitis: a prospective longitudinal observational cohort study [PDF]
, 2012 INTRODUCTION: The aim of this study was to investigate the effect of three years of tumor necrosis factor-alpha (TNF-alpha) blocking therapy on bone turnover as well as to analyze the predictive value of early changes in bone turnover markers (BTM) for ...
Eveline van der Veer +18 more
core +2 more sources
Anti-TNF therapy in inflammatory bowel disease: addressing barriers to long-term therapy
, 2022 Anti-TNF agents represent important therapeutics in Crohn’s disease and ulcerative colitis; however, there are barriers to their long-term use. First, anti-TNF agents represent a major driver of healthcare expenditure, highlighting the need to consider ...
Ashish Srinivasan (9209930)
core +1 more source